The international accelerator biobridge-2019 is going to pick up the best drug development projects to attract venture investments

On July 25, 2019, during the Selection Day at the Boiling Point ASI in Moscow, we will finally choose the strongest projects of the acceleration program biobridge-2019. 25+ teams invited to the Selection Day will showcase their developments to our expert jury during the pitch session, and the best 10–15 teams will be picked up for the program.

The international accelerator biobridge-2019 is organized by the NeuroNet Industry Union, ChemRar Group, and RDI Group powered by the Russian Ministry of Industry and Trade, RVC JSC, and the Skolkovo Foundation. The accelerator conducts a competition of the strongest projects in the field of research and development of innovative pharmaceuticals and new treatment methods, and determines the most innovative projects with the highest export potential. All projects undergo a thorough examination and consult with the leading industry experts.

For 3 months of preliminary analysis at biobridge-2019, we have examined about 300 specialized teams and invited 45 of them from various medical fields to face-to-face meetings (pre-selection). The purpose of such meetings is to provide experts and participants with the opportunity to get familiar with each other in-person and deep dive into the projects, and also provide the teams with better understanding of the program and quick feedbacks from experts to identify the directions of further work.

In the next 1.5 months, the teams picked up during the Selection Day will be participating in multiple training activities and individual work with mentors and experts who, in turn, will try to do their best to help these projects find partners and investors for the development commercialization and entrance to both Russian and European markets.

Taking into account the key goals of the new venture fund in the pharmaceutical and medical industries and its support from RVC and the Ministry of Industry and Trade of the Russian Federation, chances are that the finalists of biobridge-2019 accelerator will be the first to receive the funding.

For example, during the business breakfast on July 3, 2019, where the key parameters of the joint venture fund of RVC and the Ministry of Industry and Trade of Russia were presented, Sergey Tsyb, the First Deputy Minister of Industry and Trade of the Russian Federation, said the following: “It is important for us to use the created venture fund for driving the most disruptive pharmaceutical and medical technologies capable to raise the bar in their industries”.

Alexey Basov, Investment Director at RVC, during the presentation of the new venture fund, July 03, 2019 (photo from public sources)

During the presentation of the venture fund, Alexey Basov, Investment Director at RVC, also noted: “We hope to create a critical mass of products capable to drive our market of medical devices and pharmaceuticals while showing their applicability, scalability and readiness for the new technologies, process digitalization, new sales channels and new role types on the sophisticated market”.

In September, the projects will present their developments to industrial partners and investors at the Demo Days in Moscow and Vienna (Austria) during the contemporary art fair viennacontemporary, one of the world’s TOP-10 contemporary art events with 118 galleries from 27 countries. viennacontemporary is a week-long cultural event that attracts the European business elite and reconciles technological and business events with the exhibition of contemporary art.

BioBridge-2019 tracks:
Discovery: In-vitro developments — innovative mechanisms of action and biotargets;
Development: Innovative in-vivo pharmaceutials — proof-of-concept in pre-clinical studies;
Go2Market: Innovative projects in clinical development — proof-of-concept in clinical studies, Russia and EU market entry;
Digital Drugs: Innovative treatment methods and digital drugs using AI and big data.

Partners seeking to extend their portfolios with innovative products are also welcome to participate.

Cooperation with participants: Andrey Sizyukhin  sa@chemrar.ru

Cooperation with partners: Andrey Bogdanov ab@biobridge2019.ru

Information partnership: Elena Surina es@chemrar.ru

Program Operator: “Mestorozhdenie” LLC, Vladimir Korovin, vpkor@mail.ru

For more details on biobridge-2019, please visit www.biobridge2019.ru